Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

2022504 citationsJournal Articlehybrid Open Access

Authors

Sinéad Delany‐Moretlwe

James P. Hughes · Fred Hutch Cancer Center

Peter Bock · Stellenbosch University

Samuel Gurrion Ouma · Kenya Medical Research Institute

Portia Hunidzarira · University of Zimbabwe

Dishiki Kalonji · South African Medical Research Council

Noel Kayange · University of Malawi

Abstract

National Institute of Allergy and Infectious Diseases, ViiV Healthcare, and the Bill & Melinda Gates Foundation. Additional support was provided through the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. ViiV Healthcare and Gilead Sciences provided pharmaceutical support.

Topics & Keywords

HIV/AIDS Research and Interventions HIV, Drug Use, Sexual Risk HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Lancet

Volume 399, Issue 10337, pp. 1779-1789

DOI: 10.1016/s0140-6736(22)00538-4

Field-Weighted Citation Impact: 48.79